New drug HuL001 tested in humans for first time to fight lung scarring
NCT ID NCT04540770
First seen Sep 30, 2025 · Last updated May 05, 2026 · Updated 34 times
Summary
This early-stage study tested a new drug, HuL001, in 24 people to see if it is safe and how the body processes it. The trial included both healthy volunteers and patients with idiopathic pulmonary fibrosis, a serious lung disease that causes scarring. Researchers monitored side effects and checked how the drug moves through the body. This is a first step to see if HuL001 could help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mackay Memorial Hospital
New Taipei City, Taiwan
-
National Taiwan University Hospital
Taipei, Taiwan
Conditions
Explore the condition pages connected to this study.